Researchers at the University of California, Irvine (UCI) and NCI seek licensing for a new family of far-red to near-infrared emission coumarin-based luciferins (CouLuc) with complementary mutant enzymes.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for single domain antibodies targeting program death ligand 1 (PD-L1) for treatment of PD-L1-expressing cancers.
National Cancer Institute (NCI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seek licensees for a technology involving the preparation and use of personalized tumor vaccines for cancer immunotherapy employing a therapeutic strategy called MBTA. MBTA consists of vaccinations with irradiated tumor cells pulsed with phagocytic agonists (Mannan-BAM, a polysaccharide derivative of mannan), TLR (Toll-like receptor) ligands, and agonistic Anti-CD40-monoclonal antibody.
Researchers at the National Cancer Institute have developed a glypican-1 (GPC1) chimeric antigen receptor (CAR)-T cells using short immunoglobin subclass 4 (IgG4) hinge sequences that are highly potent against GPC1-expressing tumors. NCI seeks research co-development partners and/or licensees to advance the development of GPC1-IgG4 hinge CARs for the treatment of pancreatic cancer and other GPC1-expressing tumors.
There is a marked increase in immunosuppressive myeloid progenitors and myeloid cells in tumors and at metastatic tissue sites, rendering these types of cells useful in cancer therapeutics – especially after genetic modifications to improve their anti-tumor properties.
The National Cancer Institute (NCI) seeks research co-development or licensing for genetically engineered myeloid cells (GEMys) for use in cancer immunotherapy.
Researchers at the National Cancer Institute (NCI) have discovered a small molecule that binds to CD206 and activates M2-like tumor associated macrophages resulting in innate and adaptive anti-tumor responses. NCI seeks research co-development or licensees for CD206 small molecule modulators as a therapeutic for CD206-expressing cancers (such as pancreatic, sarcoma, head and neck, lung, gastric, triple negative breast, renal cell, colorectal cancer, melanoma).
Scientists at the National Cancer Institute (NCI) have discovered a bacterial exonuclease VII (ExoVII) inhibitor that increases the potency of widely used quinolone antibiotics targeting prokaryotic type IIA topoisomerases. NCI seeks research co-development partners and/or licensees for the development of ExoVII inhibitors as new antibiotic adjuvants to boost the efficacy of quinolone antibiotics and/or restore the susceptibility of resistant bacteria.
Researchers at the National Cancer Institute (NCI) developed a potential nucleic acid-based therapy using an inducible activation nucleic acid hybrid switch for conditional generation of oligonucleotides. The NCI seeks innovative companies interested in co-developing and/or licensing this technology.
The National Cancer Institute (NCI) seeks licensees for a collection of T-cell receptors (TCRs) that specifically target the CD20 antigen expressed in B-lymphoid malignancies such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCRs are being developed as therapeutics for the treatment of lymphomas and leukemias.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for further development of novel iodonium analogs. These iodonium analogs inhibit NADPH oxidases (NOX) and other flavin dehydrogenases to slow tumor growth.
The National Cancer Institute (NCI) seeks licensees for a collection of novel T-cell receptors (TCRs) that target the Epstein Barr Virus Latent Membrane Protein 2 (EBV-LMP2). The TCRs are being developed as therapeutics for treatment of lymphomas and epithelial cancers.
The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.
Researchers at the National Cancer Institute (NCI) developed a method of producing larger populations of minimally-differentiated, persistent T-cells, which is critical for successful treatments, using p38 mitogen-activated protein kinase (MAPK) inhibitors. NCI seeks licensing and/or co-development research collaborations to further develop, evaluate, and/or commercialize this new method.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the sulfatide analog, C24:2, that is capable of activating tumor killing type II NKT cells and reducing cancer metastasis to the lung.
The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for oxynitidine derivatives as new topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors for treating cancer. These TOP1 and TDP1 inhibitors administered in combination display increased anti-tumor potency.
Increased cyclin-dependent kinase 5 (CDK5) activity has recently emerged as a contributor to cancer progression. Researchers at the National Cancer Institute (NCI) and at the National Institute of Neurological Disorders and Stroke (NINDS) have shown that TP5, a small peptide inhibitor of CDK5 modified to facilitate passage through the blood brain barrier (BBB), has potential therapeutic benefit in glioblastoma (GBM) and colorectal carcinoma (CRC). NCI is seeking parties interested in co-developing and/or licensing TP5 for its use in the treatment of cancers with aberrant CDK5 expression as a mono-therapy or in an adjuvant setting with current standard-of-care.
The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Acetalax is a previously FDA approved drug that has been used as a topical laxative but is being repurposed here as an onco-therapy because of its cytotoxic effects on a number of TNBC and other cancer cell lines.